| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of Ethylene dimethanesulfonate include Leydig cells (LCs) and the apoptosis pathway. As a mild alkylating agent, it induces selective pro-apoptotic effects on LCs. The compound is also used as a PEG-based PROTAC linker for the synthesis of PROTAC molecules. It does not have a defined receptor target but exerts its effects through alkylation and apoptosis induction.
|
|---|---|
| ln Vitro |
In vitro, Ethylene dimethanesulfonate demonstrates selective pro-apoptotic effects on LCs (Leydig cells). As a mild alkylating agent, it induces apoptosis in LCs through alkylation of cellular components. The compound is also used as a PEG-based PROTAC linker in the synthesis of PROTAC molecules. The exact IC₅₀ values for apoptosis induction are not provided in the available literature.
|
| ln Vivo |
In rats, sperm granuloma development is caused by ethylene dimethanesulfonate (subcutaneous injection; 75 mg/kg; 7 days) and this interferes with epididymal function [1].
In vivo, Ethylene dimethanesulfonate has been shown to disrupt epididymal function when administered subcutaneously at 75 mg/kg for 7 days. The compound induces selective apoptosis in LCs, leading to reduced testosterone production and disruption of reproductive function. The in vivo effects are dose-dependent and have been characterized in animal models. However, detailed pharmacokinetic data are limited. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Ethylene dimethanesulfonate are not well established, as the compound is primarily studied for its pro-apoptotic effects and use as a PROTAC linker. Quality control assays typically involve HPLC analysis to verify purity. The compound's alkylating activity can be assessed by its ability to modify cellular proteins and DNA.
|
| Cell Assay |
In vitro cellular assays for Ethylene dimethanesulfonate involve testing its pro-apoptotic effects on LCs and other cell types. Cells are treated with varying concentrations of Ethylene dimethanesulfonate (0.1-100 µM) for 24-72 hours. Apoptosis is measured by Annexin V/PI staining, caspase activity assays, and DNA fragmentation analysis. The compound demonstrates selective pro-apoptotic effects on LCs.
|
| Animal Protocol |
In vivo animal studies for Ethylene dimethanesulfonate involve testing its effects on reproductive function. Male rats or mice are treated with Ethylene dimethanesulfonate via subcutaneous injection at various doses (typically 25-100 mg/kg). Leydig cell apoptosis, testosterone levels, and epididymal function are assessed after 7-14 days. The compound demonstrates dose-dependent effects on LC survival and reproductive function.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Ethylene dimethanesulfonate include a molecular weight of 218.25 and a molecular formula of C₄H₁₀O₆S₂. The compound is a mild alkylating agent and is used as a PROTAC linker. Detailed pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution are not well characterized in the available literature. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Ethylene dimethanesulfonate is associated with its alkylating activity and pro-apoptotic effects. The compound induces selective apoptosis in LCs, which can lead to reproductive toxicity. Standard toxicity studies include assessment of body weight changes, hematological parameters, and histopathological examination of reproductive organs in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References |
[1]. Dutta D, et al. Ethylene dimethane sulfonate (EDS) ablation of Leydig cells in adult rat depletes testosterone resulting in epididymal sperm granuloma: Testosterone replacement prevents granuloma formation. Reprod Biol. 2019 Mar;19(1):89-99.
|
| Additional Infomation |
Ethylene dimethanesulfonate (CAS 4672-49-5) has a molecular formula of C₄H₁₀O₆S₂ and a molecular weight of 218.25. It is a mild alkylating, non-volatile methanesulfonic acid diester of ethylene glycol with selective pro-apoptotic effects on LCs. The compound is also used as a PEG-based PROTAC linker. It is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
C4H10O6S2
|
|---|---|
| Molecular Weight |
218.25
|
| Exact Mass |
217.992
|
| CAS # |
4672-49-5
|
| Related CAS # |
52410-74-9
|
| PubChem CID |
20796
|
| Appearance |
White to off-white solid powder
|
| Density |
1.461g/cm3
|
| Boiling Point |
448.9ºC at 760 mmHg
|
| Melting Point |
35-36℃
|
| Flash Point |
225.3ºC
|
| Index of Refraction |
1.47
|
| LogP |
1.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
266
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CS(=O)(=O)OCCOS(=O)(=O)C
|
| InChi Key |
QSQFARNGNIZGAW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H10O6S2/c1-11(5,6)9-3-4-10-12(2,7)8/h3-4H2,1-2H3
|
| Chemical Name |
2-methylsulfonyloxyethyl methanesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (458.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5819 mL | 22.9095 mL | 45.8190 mL | |
| 5 mM | 0.9164 mL | 4.5819 mL | 9.1638 mL | |
| 10 mM | 0.4582 mL | 2.2910 mL | 4.5819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
